Streamex Corp. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Streamex Corp. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $18.0K | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $286.0K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $441.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 31, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $40.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $18.0K | Apr 15, 2025 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $18.0K | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $229.0K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $242.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 31, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($462.78M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($10.33M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($29.04M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($27.05M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($31.92M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($52.22M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($34.06M) | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | ($18.14M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($12.70M) | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | ($11.59M) | Feb 27, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($71.09M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($12.86M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($28.51M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($27.27M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($33.41M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($59.18M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($34.60M) | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | ($17.26M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($12.91M) | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | ($11.16M) | Feb 27, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $832.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $5.09M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $5.82M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $5.60M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $18.14M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $9.74M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $4.37M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $4.76M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $2.65M | Feb 27, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.44M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($4.76M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($17.31M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($21.71M) | Apr 16, 2024 |
| FY2021 | Mar 30, 2022 | $26.40M | Mar 31, 2022 |
| FY2022 | Dec 31, 2021 | ($26.40M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($26.60M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($15.48M) | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | ($10.26M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($7.47M) | Mar 15, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $186.0K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $168.0K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $542.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $87.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $177.0K | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $38.0K | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $9.4K | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $16.3K | Feb 27, 2018 |
| FY2016 | Dec 31, 2015 | $15.9K | Apr 11, 2017 |
| FY2015 | Dec 31, 2014 | $4.0K | Mar 14, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $187.54M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $842.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $1.80M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $4.11M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $15.52M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $30.39M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $14.22M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $5.00M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $1.70M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $1.24M | Feb 27, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $54.22M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $2.26M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $4.69M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $3.71M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $2.95M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $5.11M | Mar 31, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $133.19M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($1.54M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($3.02M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $313.0K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $12.24M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $24.37M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $11.15M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $3.32M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($3.25M) | Mar 15, 2019 |
| FY2018 | Dec 31, 2016 | ($2.79M) | Mar 15, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $70.98M | Mar 31, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($718.12M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($255.35M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($245.02M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($215.97M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($188.92M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($157.01M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($104.79M) | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | ($70.73M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($56.52M) | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | ($43.83M) | Feb 27, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.30M | Mar 31, 2026 |
| FY2023 | Dec 31, 2023 | $200.0K | Apr 16, 2024 |
| FY2022 | Dec 31, 2022 | $400.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2021 | $11.70M | Mar 31, 2022 |
| FY2020 | Dec 31, 2020 | $28.27M | Mar 15, 2021 |
| FY2020 | Dec 31, 2019 | $12.11M | Mar 15, 2021 |
| FY2020 | Dec 31, 2018 | $4.45M | Mar 15, 2021 |
| FY2019 | Dec 31, 2017 | $1.55M | Mar 13, 2020 |
| FY2018 | Dec 31, 2016 | $1.06M | Mar 15, 2019 |
| FY2017 | Dec 31, 2015 | $953.2K | Feb 27, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (9) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | (6) | Apr 16, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (9) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | (6) | Apr 16, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 49.81M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 17.24M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 9.04M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 5.51M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 35.57M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 30.76M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 23.32M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | 16.87M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | 11.73M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | 22.59M | Feb 27, 2018 |